The Pro Medicus Limited (ASX: PME) share price failed to take off on Thursday due to weakness in the tech sector.
This was despite the health imaging technology company announcing a major new contract win.
What did Pro Medicus announce?
Yesterday, Pro Medicus announced a $28 million, seven-year contract with Allina Health. It is a not-for-profit health care system based in Minneapolis with 28,000 employees across 11 hospitals and more than 90 clinics.
The contract is based on a transactional licensing model and will see the company’s increasingly popular Visage 7 Enterprise Imaging Platform and Visage 7 Workflow module implemented throughout Allina Health. This will provide it with a unified diagnostic imaging platform across the network.
What was the response?
While the market’s response was subdued, analysts at Bell Potter were very pleased with the news.
According to a note, Bell Potter believes this new contract win highlights that Visage could “be the emerging standard for the viewing of radiology images in the US.”
In addition, the broker was pleased to see management commenting that its sales pipeline remains strong. It said:
[T]he CEO has again described the pipeline as “remaining strong”. The same phrase has consistently been used to describe the pipeline for several years and the company is yet to disappoint the market’s expectation for revenue growth.
We maintain our expectation of ongoing growth in contracts noting that PME has barely scratched the surface of the IDN market in the US. There are approximately 1,000 IDN’s operating in the US Healthcare system.
In light of this, the broker has retained its buy rating and $55.00 price target on the company’s shares.
Based on the current Pro Medicus share price, this implies potential upside of approximately 25% over the next 12 months.
The post Broker tips Pro Medicus share price to shoot 25% higher appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you consider Pro Medicus, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- 5 things to watch on the ASX 200 on Friday
- ASX 200 midday update: Pilbara Minerals names new CEO, Wesfarmers’ strategy update
- Pro Medicus share price falls despite major contract win
- Here are 3 highly profitable shares I’ll be buying this month
- Best ASX shares to buy in June 2022
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/AVoivck
Stock Pick 